199 related articles for article (PubMed ID: 10446977)
1. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment.
Froidevaux S; Hintermann E; Török M; Mäcke HR; Beglinger C; Eberle AN
Cancer Res; 1999 Aug; 59(15):3652-7. PubMed ID: 10446977
[TBL] [Abstract][Full Text] [Related]
2. Tetraamine-modified octreotide and octreotate: labeling with 99mTc and preclinical comparison in AR4-2J cells and AR4-2J tumor-bearing mice.
Nikolopoulou A; Maina T; Sotiriou P; Cordopatis P; Nock BA
J Pept Sci; 2006 Feb; 12(2):124-31. PubMed ID: 16059963
[TBL] [Abstract][Full Text] [Related]
3. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
4. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide.
Fisher WE; Muscarella P; O'Dorisio TM; O'Dorisio MS; Kim JA; Doran TA; Sabourin CL; Schirmer WJ
Surgery; 1996 Aug; 120(2):234-40; discussion 240-1. PubMed ID: 8751588
[TBL] [Abstract][Full Text] [Related]
5. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
Weckbecker G; Raulf F; Bodmer D; Bruns C
Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
[TBL] [Abstract][Full Text] [Related]
6. Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.
Waser B; Cescato R; Tamma ML; Maecke HR; Reubi JC
Eur J Pharmacol; 2010 Oct; 644(1-3):257-62. PubMed ID: 20643121
[TBL] [Abstract][Full Text] [Related]
7. 17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo.
Visser-Wisselaar HA; Van Uffelen CJ; Van Koetsveld PM; Lichtenauer-Kaligis EG; Waaijers AM; Uitterlinden P; Mooy DM; Lamberts SW; Hofland LJ
Endocrinology; 1997 Mar; 138(3):1180-9. PubMed ID: 9048625
[TBL] [Abstract][Full Text] [Related]
8. A microplate binding assay for the somatostatin type-2 receptor (SSTR2).
Froidevaux S; Meier M; Häusler M; Mäcke H; Beglinger C; Eberle AN
J Recept Signal Transduct Res; 1999; 19(1-4):167-80. PubMed ID: 10071756
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma.
Hua YP; Yin XY; Peng BG; Li SQ; Lai JM; Liang HZ; Liang LJ
Chemotherapy; 2009; 55(5):312-20. PubMed ID: 19590186
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin analog inhibits the growth of insulinoma cells by p27-mediated G1 cell cycle arrest.
Aoki T; Motoi F; Sakata N; Naitoh T; Katayose Y; Egawa S; Miyazaki J; Unno M
Pancreas; 2014 Jul; 43(5):720-9. PubMed ID: 24694834
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
12. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors.
Oda Y; Tanaka Y; Naruse T; Sasanabe R; Tsubamoto M; Funahashi H
Surg Today; 2002; 32(8):690-4. PubMed ID: 12181718
[TBL] [Abstract][Full Text] [Related]
13. In vitro modeling of the clinical interactions between octreotide and 111In-pentetreotide: is there evidence of somatostatin receptor downregulation?
Gunn SH; Schwimer JE; Cox M; Anthony CT; O'Dorisio MS; Woltering EA
J Nucl Med; 2006 Feb; 47(2):354-9. PubMed ID: 16455643
[TBL] [Abstract][Full Text] [Related]
14. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
15. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector.
Rogers BE; McLean SF; Kirkman RL; Della Manna D; Bright SJ; Olsen CC; Myracle AD; Mayo MS; Curiel DT; Buchsbaum DJ
Clin Cancer Res; 1999 Feb; 5(2):383-93. PubMed ID: 10037188
[TBL] [Abstract][Full Text] [Related]
16. Regulation of ghrelin secretion by somatostatin analogs in rats.
Silva AP; Bethmann K; Raulf F; Schmid HA
Eur J Endocrinol; 2005 Jun; 152(6):887-94. PubMed ID: 15941929
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
Hubina E; Nanzer AM; Hanson MR; Ciccarelli E; Losa M; Gaia D; Papotti M; Terreni MR; Khalaf S; Jordan S; Czirják S; Hanzély Z; Nagy GM; Góth MI; Grossman AB; Korbonits M
Eur J Endocrinol; 2006 Aug; 155(2):371-9. PubMed ID: 16868153
[TBL] [Abstract][Full Text] [Related]
18. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients.
Reubi JC; Waser B; Cescato R; Gloor B; Stettler C; Christ E
J Clin Endocrinol Metab; 2010 May; 95(5):2343-50. PubMed ID: 20228164
[TBL] [Abstract][Full Text] [Related]
19. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
[TBL] [Abstract][Full Text] [Related]
20. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
